These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 17059856)

  • 1. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
    Boone JD; Balasuriya UB; Karaca K; Audonnet JC; Yao J; He L; Nordgren R; Monaco F; Savini G; Gardner IA; Maclachlan NJ
    Vaccine; 2007 Jan; 25(4):672-8. PubMed ID: 17059856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
    Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
    Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants.
    Perrin A; Albina E; Bréard E; Sailleau C; Promé S; Grillet C; Kwiatek O; Russo P; Thiéry R; Zientara S; Cêtre-Sossah C
    Vaccine; 2007 Sep; 25(37-38):6774-83. PubMed ID: 17669563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
    Calvo-Pinilla E; Rodríguez-Calvo T; Sevilla N; Ortego J
    Vaccine; 2009 Dec; 28(2):437-45. PubMed ID: 19857449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus.
    Top S; Foucras G; Deplanche M; Rives G; Calvalido J; Comtet L; Bertagnoli S; Meyer G
    Vaccine; 2012 Feb; 30(9):1609-16. PubMed ID: 22244980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
    Hamers C; Rehbein S; Hudelet P; Blanchet M; Lapostolle B; Cariou C; Duboeuf M; Goutebroze S
    Vaccine; 2009 May; 27(21):2789-93. PubMed ID: 19366576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge.
    Wade-Evans AM; Romero CH; Mellor P; Takamatsu H; Anderson J; Thevasagayam J; Fleming MJ; Mertens PP; Black DN
    Virology; 1996 Jun; 220(1):227-31. PubMed ID: 8659119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
    Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
    Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
    Kochinger S; Renevey N; Hofmann MA; Zimmer G
    Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines against bluetongue in Europe.
    Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
    Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nature and duration of protective immunity to bluetongue virus infection.
    Roy P
    Dev Biol (Basel); 2003; 114():169-83. PubMed ID: 14677687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bluetongue virus: virology, pathogenesis and immunity.
    Schwartz-Cornil I; Mertens PP; Contreras V; Hemati B; Pascale F; Bréard E; Mellor PS; MacLachlan NJ; Zientara S
    Vet Res; 2008; 39(5):46. PubMed ID: 18495078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen.
    Franceschi V; Capocefalo A; Calvo-Pinilla E; Redaelli M; Mucignat-Caretta C; Mertens P; Ortego J; Donofrio G
    Vaccine; 2011 Apr; 29(16):3074-82. PubMed ID: 21320537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.
    El Garch H; Crafford JE; Amouyal P; Durand PY; Edlund Toulemonde C; Lemaitre L; Cozette V; Guthrie A; Minke JM
    Vet Immunol Immunopathol; 2012 Sep; 149(1-2):76-85. PubMed ID: 22763149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus.
    Barros SC; Cruz B; Luís TM; Ramos F; Fagulha T; Duarte M; Henriques M; Fevereiro M
    Vet Microbiol; 2009 Jun; 137(3-4):252-9. PubMed ID: 19233575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.